BIOMAT Database Logo BIOMAT Database Logo

Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. 2001

D J Hoban, and S K Bouchillon, and J L Johnson, and G G Zhanel, and D L Butler, and L A Miller, and J A Poupard, and
Laboratories International for Microbiology Studies, Rolling Meadows, IL, USA. dhoban@ihmainc.com

The in vitro activity of gemifloxacin, a new fluoroquinolone, was compared to three marketed fluoroquinolones; ciprofloxacin, levofloxacin and ofloxacin against over 4,000 recent clinical isolates covering 29 species isolated in the United States and Canada between 1997-1999. Based on MIC(90)s, gemifloxacin was the most potent fluoroquinolone tested against a majority of Gram-positive isolates: Streptococcus pneumoniae, penicillin resistant S. pneumoniae, macrolide resistant S. pneumoniae, ciprofloxacin non-susceptible (MIC > or = 4 microg/mL) S. pneumoniae, S. pyogenes, S. agalactiae, viridans streptococci, Enterococcus faecalis, methicillin susceptible Staphylococcus aureus, methicillin resistant S. aureus, S. epidermidis, S. hemolyticus, and S. saprophyticus. Against Enterobacteriaceae and aerobic non-Enterobacteriaceae Gram-negatives, gemifloxacin was usually comparable to ciprofloxacin and levofloxacin and more potent than ofloxacin for the following species: Citrobacter freundii, Enterobacter aerogenes, E. cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, P. vulgaris, Providencia stuartii, Serratia marcescens, Acinetobacter lwoffii, A. baumannii, Burkholderia cepacia, Haemophilus influenzae, H. parainfluenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. Gemifloxacin was generally 16-64 fold more potent than the other fluoroquinolones tested against Gram-positive organisms and retains excellent activity comparable with ciprofloxacin and levofloxacin against a majority of Gram-negative pathogens.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009287 Naphthyridines A group of two-ring heterocyclic compounds consisting of a NAPHTHALENES double ring in which two carbon atoms, one per each ring, are replaced with nitrogens.
D011159 Population Surveillance Ongoing scrutiny of a population (general population, study population, target population, etc.), generally using methods distinguished by their practicability, uniformity, and frequently their rapidity, rather than by complete accuracy. Surveillance, Population
D002170 Canada The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D006094 Gram-Positive Bacteria Bacteria which retain the crystal violet stain when treated by Gram's method. Gram Positive Bacteria
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077735 Gemifloxacin A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis. 7-(3-aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid,Factive,Gemifloxacin Mesylate,LB 20304,LB-20304,LB20304,SB 265805,SB-265805,SB265805
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.

Related Publications

D J Hoban, and S K Bouchillon, and J L Johnson, and G G Zhanel, and D L Butler, and L A Miller, and J A Poupard, and
Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin.
April 1994, Journal of chemotherapy (Florence, Italy),
D J Hoban, and S K Bouchillon, and J L Johnson, and G G Zhanel, and D L Butler, and L A Miller, and J A Poupard, and
Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates.
April 2004, Cornea,
D J Hoban, and S K Bouchillon, and J L Johnson, and G G Zhanel, and D L Butler, and L A Miller, and J A Poupard, and
In vitro activity of ciprofloxacin, ofloxacin and levofloxacin against Mycobacterium tuberculosis.
January 2005, Annals of Saudi medicine,
D J Hoban, and S K Bouchillon, and J L Johnson, and G G Zhanel, and D L Butler, and L A Miller, and J A Poupard, and
North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.
January 1994, Diagnostic microbiology and infectious disease,
D J Hoban, and S K Bouchillon, and J L Johnson, and G G Zhanel, and D L Butler, and L A Miller, and J A Poupard, and
Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria.
May 1996, Diagnostic microbiology and infectious disease,
D J Hoban, and S K Bouchillon, and J L Johnson, and G G Zhanel, and D L Butler, and L A Miller, and J A Poupard, and
In-vitro activity of ofloxacin, levofloxacin and D-ofloxacin against staphylococci.
August 1996, The Journal of antimicrobial chemotherapy,
D J Hoban, and S K Bouchillon, and J L Johnson, and G G Zhanel, and D L Butler, and L A Miller, and J A Poupard, and
Comparative in vitro activity of ciprofloxacin and levofloxacin against isolated uropathogens in Ghana: a pilot study.
January 2018, The Pan African medical journal,
D J Hoban, and S K Bouchillon, and J L Johnson, and G G Zhanel, and D L Butler, and L A Miller, and J A Poupard, and
In-vitro activity of levofloxacin (l-ofloxacin), ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales.
November 1996, The Journal of antimicrobial chemotherapy,
D J Hoban, and S K Bouchillon, and J L Johnson, and G G Zhanel, and D L Butler, and L A Miller, and J A Poupard, and
Comparative in vitro activity of gemifloxacin.
April 2000, The Journal of antimicrobial chemotherapy,
D J Hoban, and S K Bouchillon, and J L Johnson, and G G Zhanel, and D L Butler, and L A Miller, and J A Poupard, and
Transfer of ciprofloxacin, ofloxacin and levofloxacin across the perfused human placenta in vitro.
September 2005, European journal of obstetrics, gynecology, and reproductive biology,
Copied contents to your clipboard!